Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review

Abstract Epidermal growth factor receptor (EGFR) serves as a co-target for dual/pan-EGFR-inhibitors in breast cancer. Findings suggest that EGFR and EGFR-ligands are involved in resistance towards certain breast cancer treatments. The aim is to explore the validity of EGFR and EGFR-ligands in blood as prognostic and predictive biomarkers in breast cancer. The systematic review was conducted in accordance to the PRISMA guidelines. Literature searches were conducted to identify publications exploring correlations between EGFR/EGFR-ligands in serum/plasma of breast cancer patients and prognostic/predictive outcome measures. Sixteen publications were eligible for inclusion. Twelve studies evaluated EGFR, whereas five studies evaluated one or more of the EGFR-ligands. Current evidence indicates associations between low baseline serum-EGFR and shorter survival or reduced response to treatment in patients with advanced breast cancer, especially in patients with estrogen and/or progesterone receptor positive tumors. The prognostic and predictive value of EGFR and EGFR-ligands in blood has only been investigated in highly selected subsets of breast cancer patients and most studies were small. This is the first systematic review evaluating the utility of EGFR and EGFR-ligands as predictive and prognostic biomarkers in blood in breast cancer. Further exploration in large well-designed studies is needed.

[1]  S. Tsutsui,et al.  Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer , 2004, Breast Cancer Research and Treatment.

[2]  Colin G. Johnson,et al.  The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer , 2010, Breast Cancer Research and Treatment.

[3]  V. Torri,et al.  Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[4]  A. Auvinen,et al.  HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 , 2009, Breast Cancer Research.

[5]  Pil Je Park,et al.  The multiplex bead array approach to identifying serum biomarkers associated with breast cancer , 2009, Breast Cancer Research.

[6]  G. Gasparini,et al.  Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Neumann,et al.  The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. , 2007, American journal of clinical pathology.

[8]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[9]  P. Maisonneuve,et al.  Serum EGFR and serum HER‐2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy , 2007, Cancer.

[10]  H. Fritsche,et al.  Elevated serum levels of transforming growth factor-alpha in breast cancer patients. , 1994, Cancer letters.

[11]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[12]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[13]  I. Brandslund,et al.  Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer , 2013, Clinical chemistry and laboratory medicine.

[14]  W. Eiermann,et al.  Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator , 2013, BMC Cancer.

[15]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[16]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[17]  G. Schmidt,et al.  Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase , 2015, British Journal of Cancer.

[18]  I. Brandslund,et al.  Clinical use of S-HER2 in breast cancer for detecting metastatic recurrence and monitoring effect of trastuzumab treatment , 2014 .

[19]  M. Buyse,et al.  Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[20]  E. Perez,et al.  Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. , 2005, Cancer research.

[21]  P. Shetty,et al.  Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer , 2017, Annals of clinical biochemistry.

[22]  Y. Shimada,et al.  Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer , 2014, British Journal of Cancer.

[23]  W. Carney,et al.  Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  John Mendelsohn,et al.  Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.

[25]  R. Neumann,et al.  Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. , 2006, Anticancer research.

[26]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[27]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[28]  I. Ellis,et al.  Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients , 2007, Breast Cancer Research.

[29]  S. Eccles.  The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. , 2011, The International journal of developmental biology.

[30]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[31]  W. Carney,et al.  Serum epidermal growth factor receptor/HER‐2 predicts poor survival in patients with metastatic breast cancer , 2006, Cancer.

[32]  Yusuke Nakamura,et al.  Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.

[33]  S G Thompson,et al.  Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated , 1994, BMJ.

[34]  I. Brandslund,et al.  Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients , 2013, Journal of Cancer Research and Clinical Oncology.

[35]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Tsutsui,et al.  Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[39]  S. Im,et al.  Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer , 2015, Journal of Cancer Research and Clinical Oncology.

[40]  R. Neumann,et al.  Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. , 2006, The International journal of biological markers.

[41]  A. Luini,et al.  Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. , 2009, Anticancer research.

[42]  J. Bhatavdekar,et al.  Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study , 2004, Breast Cancer Research and Treatment.

[43]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[44]  Shuang Huang,et al.  Elevated serum levels of transforming growth factor-α in breast cancer patients , 1994 .

[45]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement , 2015, Systematic Reviews.

[46]  R. Neumann,et al.  Clinical Utility of Determination of HER-2/neu and EGFR Fragments in Serum of Patients with Metastatic Breast Cancer , 2006, The International journal of biological markers.

[47]  I. Brandslund,et al.  Increased concentrations of growth factors and activation of the EGFR system in breast cancer , 2012, Clinical chemistry and laboratory medicine.

[48]  S. Im,et al.  Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.

[49]  E. Kubista,et al.  Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. , 2006, European journal of cancer.

[50]  Y. Bang,et al.  High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer , 2010, Breast Cancer Research and Treatment.

[51]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[52]  P. Neven,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2012, The New England journal of medicine.

[53]  L. Seymour,et al.  Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  F. Tas,et al.  Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer. , 2015, Cytokine.

[55]  H. Tesch,et al.  Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial , 2010, Breast Cancer Research and Treatment.